About
Pharnext
An advanced clinical-stage biopharmaceutical company
Our company
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel first-in-class therapies for orphan and common diseases with high unmet medical needs, leveraging our artificial intelligence (AI)-based PLEOTHERAPY™ platform.
Our vision
We strive to address serious unmet medical needs. We believe that diseases require solutions that master their complexity by combining therapeutics in a synergistic and/or additive way. We aim to become the recognized world leader in this approach.
Our mission
We are dedicated to treating serious chronic diseases by developing novel, first-in-class treatments.

We leverage our artificial intelligence (AI)-based PLEOTHERAPY™ platform technology to discover, develop and deliver breakthrough therapies to patients.

These therapies consist of repurposed or New Chemical Entity (NCE) drug combinations with potentially high benefit/risk ratio and an accelerated/cost-efficient development pathway.

Timeline

Explore our history since inception in 2007

2Q07
2Q07
Pharnext is founded

2Q07
4Q10
PXT3003: Launch of Phase 2 clinical trials in CMT1A

2Q07
1Q13
PXT864: Launch of Phase 2 clinical trials in Alzheimer’s disease

2Q07
2Q14
PXT3003: EMA and FDA orphan drug designation for CMT1A

2Q07
4Q14
PXT3003: Positive Phase 2 results in CMT1A

2Q07
4Q15
PXT3003: Launch of Phase 3 clinical trials in CMT1A

2Q07
3Q16
Pharnext IPO on Alternext Stock Exchange in Paris

2Q07
1Q17
R&D agreement with Galapagos to generate a new pipeline of synergistic drug combinations

2Q07
2Q17
Strategic partnership with Tasly, a leading Chinese pharmaceutical group

2Q07
4Q18
Pharnext and Vitaccess launch International CMT&Me Observational Study

2Q07
4Q18
PXT3003: Positive topline results from pivotal Phase 3 trial in CMT1A

2Q07
1Q19
PXT3003: FDA Fast Track designation for the treatment of CMT1A

2Q07
1Q20
PXT3003: Encouraging preliminary data from open-label Phase 3 extension study in CMT1A

2Q07
1Q20
PXT3003 granted “Promising Innovative Medicine” status by UK MHRA in CMT1A

Technology
PLEOTHERAPY™, our proprietary technology platform, is based on network pharmacology. This new and innovative R&D paradigm leverages genomic big data and artificial intelligence tools to systematically develop disease molecular networks: a set of interconnected potential disease targets. These networks are then used to deduce, in silico and experimentally, combinations of generic compounds approved for unrelated indications and/or NCEs to hit multiple highly relevant disease targets. These new therapies, called PLEODRUG™, are formulated at optimal doses offering several potential key advantages including improved efficacy and safety.
Drug Candidates
PLEODRUG™ candidates are currently in clinical development for the treatment of Charcot-Marie-Tooth disease type 1A and Alzheimer’s disease. We believe that this is just the beginning and that our proprietary technology is poised to provide therapies for any disease.

Meet our teams

Leadership team
Dr. David Horn Solomon
Dr. David Horn Solomon
Chief Executive Officer
Adrian Hepner, MD, PhD
Adrian Hepner, MD, PhD
Chief Medical Officer
Peter Collum, MBA
Peter Collum, MBA
Chief Financial Officer and Chief Business Officer
Xavier Paoli, MSc
Xavier Paoli, MSc
Chief Commercial Officer
Susanne Dorn, MSc
Susanne Dorn, MSc
Chief Regulatory Officer
Muriel Cottard, PhD
Muriel Cottard, PhD
Chief Quality Officer
Serguei Nabirotchkin, PhD
Serguei Nabirotchkin, PhD
Co-founder
François Chamoun, LL.M, DJCE
François Chamoun, LL.M, DJCE
General Counsel
Board of directors
Michel de Rosen
Michel de Rosen
Chairman of the Board of Directors
Alexandre Berda
Alexandre Berda
Director
Pierre Bastid
Pierre Bastid
Director
Jean Combalbert
Jean Combalbert
Director
Elisabeth Svanberg
Elisabeth Svanberg
Director
Philippe Pouletty
Philippe Pouletty
Director
Joshua Schafer
Joshua Schafer
Director
David Horn Solomon
David Horn Solomon
Director and Chief Executive Officer
Lawrence Steinman
Lawrence Steinman
Director
Kenneth Lee
Kenneth Lee
Director

Contact

Have a question for Pharnext?

Want to join our team?